Immunotherapy for chordoma and chondrosarcoma: Current evidence

Jeffrey I. Traylor, Mark N. Pernik, Aaron R. Plitt, Michael Lim, Tomas Garzon-Muvdi

Research output: Contribution to journalReview articlepeer-review

12 Scopus citations


Chordomas and chondrosarcomas are rare but devastating neoplasms that are characterized by chemoradiation resistance. For both tumors, surgical resection is the cornerstone of management. Immunotherapy agents are increasingly improving outcomes in multiple cancer subtypes and are being explored in chordoma and chondrosarcoma alike. In chordoma, brachyury has been identified as a prominent biomarker and potential molecular immunotherapy target as well as PD-1 inhibition. While studies on immunotherapy in chondrosarcoma are sparse, there is emerging evidence and ongoing clinical trials for PD-1 as well as IDH inhibitors. This review highlights potential biomarkers and targets for immunotherapy in chordoma and chondrosarcoma, as well as current clinical evidence and ongoing trials.

Original languageEnglish (US)
Article number2408
Issue number10
StatePublished - May 2 2021


  • Brachyury
  • Chondrosarcoma
  • Chordoma
  • Immunotherapy
  • PD-1

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Immunotherapy for chordoma and chondrosarcoma: Current evidence'. Together they form a unique fingerprint.

Cite this